Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD19 targeting CAR-T cell therapy - EdiGene

Next Previous
X
Search
Drug Profile

CD19 targeting CAR-T cell therapy - EdiGene

Alternative Names: ATHENA CAR-T - EdiGene; ATHENA CD19-directed chimeric antigen receptor -T Cell - EdiGene

Latest Information Update: 20 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EdiGene Inc
  • Developer EdiGene Inc; Peking University
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 31 May 2024 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Non-Hodgkin's lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 15 Apr 2024 Phase-I clinical trials in Systemic lupus erythematosus (Treatment-experienced) in China (Parenteral) (NCT06373991)
  • 29 Sep 2023 Phase-I/II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, In adults, In the elderly) in China (Parenteral) (NCT06014073)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top